BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Taiho Pharmaceutical readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies Taiho Pharmaceutical's drugs run\
 , from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05676931-2695@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Quemliclustat: Phase 2 readout est. (NCT05676931)
DESCRIPTION:Quemliclustat\, phase 2.\nStudy: Study With Various Immunothera
 py Treatments in Participants With Lung Cancer\nEstimated primary completi
 on: December 2027. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/qu
 emliclustat#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT05676931
URL:https://assetmemo.bio/drug/quemliclustat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07011719-10820@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20280430
DTEND;VALUE=DATE:20280501
SUMMARY:Casdatifan: Phase 3 readout est. (NCT07011719)
DESCRIPTION:Casdatifan\, phase 3\, Clear Cell Renal Cell Carcinoma.\nStudy:
  Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in P
 atients With Advanced Clear Cell Renal Cell Carcinoma\nEstimated primary c
 ompletion: April 2028. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/casdatifan#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT07011719
URL:https://assetmemo.bio/drug/casdatifan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04683250-2757@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20300331
DTEND;VALUE=DATE:20300401
SUMMARY:Vepafestinib: Phase 1/2 readout est. (NCT04683250)
DESCRIPTION:Vepafestinib\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: 
 Study of RET Inhibitor TAS0953/HM06 in Patients With Advanced Solid Tumors
  With RET Gene Abnormalities\nEstimated primary completion: March 2030. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/vepafestinib#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT04683250
URL:https://assetmemo.bio/drug/vepafestinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07710885-2756@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20300430
DTEND;VALUE=DATE:20300501
SUMMARY:Futibatinib (Lytgobi): Phase 3 readout est. (NCT07710885)
DESCRIPTION:Futibatinib (Lytgobi)\, phase 3\, Biliary Tract Cancer.\nStudy:
  Futibatinib (TAS-120) in Patients With Advanced Biliary Tract Cancer\nEst
 imated primary completion: 30 April 2030. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/futibatinib-lytgobi#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT07710885
URL:https://assetmemo.bio/drug/futibatinib-lytgobi#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06608927-2695@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20301130
DTEND;VALUE=DATE:20301201
SUMMARY:Quemliclustat: Phase 3 readout est. (NCT06608927)
DESCRIPTION:Quemliclustat\, phase 3\, Pancreatic Ductal Adenocarcinoma.\nSt
 udy: Study of Quemliclustat and Chemotherapy Versus Placebo and Chemothera
 py in Patients With Metastatic Pancreatic Ductal Adenocarcinoma\nEstimated
  primary completion: 30 November 2030. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/quemliclustat#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT06608927
URL:https://assetmemo.bio/drug/quemliclustat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
